MA40606A - (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyéthyl]-4-(4-méthoxy-3-{[1-(5-méthylpyridin-2-yl)azétidin-3-yl]oxy}phényl) -3-méthylpyrrolidin-1-yl]-3-oxopropane-1,2-diol cristallin - Google Patents

(2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyéthyl]-4-(4-méthoxy-3-{[1-(5-méthylpyridin-2-yl)azétidin-3-yl]oxy}phényl) -3-méthylpyrrolidin-1-yl]-3-oxopropane-1,2-diol cristallin

Info

Publication number
MA40606A
MA40606A MA040606A MA40606A MA40606A MA 40606 A MA40606 A MA 40606A MA 040606 A MA040606 A MA 040606A MA 40606 A MA40606 A MA 40606A MA 40606 A MA40606 A MA 40606A
Authority
MA
Morocco
Prior art keywords
oxopropane
methylpyrrolidin
azetidin
methylpyridin
oxy
Prior art date
Application number
MA040606A
Other languages
English (en)
Inventor
Ping Huang
Seth Dietrich Ribe
Original Assignee
Lilly Co Eli
Lilly China Res And Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Lilly China Res And Development Co Ltd filed Critical Lilly Co Eli
Publication of MA40606A publication Critical patent/MA40606A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne le (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyéthyl]-4-(4-méthoxy-3-{[1-(5-méthylpyridin-2-yl)azétidin-3-yl]oxy}phényl)-3-méthylpyrrolidin-1-yl]-3-oxopropane-1,2-diol cristallin et des compositions pharmaceutiques de celui-ci. L'invention concerne également des procédés d'utilisation de ce composé pour le traitement de la vessie hyperactive.
MA040606A 2014-09-04 2015-08-28 (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyéthyl]-4-(4-méthoxy-3-{[1-(5-méthylpyridin-2-yl)azétidin-3-yl]oxy}phényl) -3-méthylpyrrolidin-1-yl]-3-oxopropane-1,2-diol cristallin MA40606A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2014/085925 WO2016033776A1 (fr) 2014-09-04 2014-09-04 (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyéthyl]-4-(4-méthoxy-3-{[1-(5-méthylpyridin-2-yl)azétidin-3-yl]oxy}phényl)-3-méthylpyrrolidin-1-yl]-3-oxopropane-1,2-diol cristallin

Publications (1)

Publication Number Publication Date
MA40606A true MA40606A (fr) 2016-03-10

Family

ID=54073019

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040606A MA40606A (fr) 2014-09-04 2015-08-28 (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyéthyl]-4-(4-méthoxy-3-{[1-(5-méthylpyridin-2-yl)azétidin-3-yl]oxy}phényl) -3-méthylpyrrolidin-1-yl]-3-oxopropane-1,2-diol cristallin

Country Status (26)

Country Link
US (1) US10065942B2 (fr)
EP (1) EP3189044B1 (fr)
JP (1) JP6364545B2 (fr)
KR (1) KR20170038884A (fr)
CN (1) CN107001327B (fr)
AP (1) AP2017009774A0 (fr)
AU (1) AU2015312229B2 (fr)
BR (1) BR112017003010A2 (fr)
CA (1) CA2956517A1 (fr)
CL (1) CL2017000467A1 (fr)
CO (1) CO2017001097A2 (fr)
CR (1) CR20170051A (fr)
DO (1) DOP2017000037A (fr)
EA (1) EA031089B1 (fr)
EC (1) ECSP17013015A (fr)
ES (1) ES2688167T3 (fr)
IL (1) IL250356A0 (fr)
MA (1) MA40606A (fr)
MX (1) MX2017002688A (fr)
NZ (1) NZ728359A (fr)
PE (1) PE20170442A1 (fr)
PH (1) PH12017500400A1 (fr)
SG (1) SG11201701608RA (fr)
TN (1) TN2017000045A1 (fr)
TW (1) TWI570119B (fr)
WO (2) WO2016033776A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101696A1 (es) * 2014-09-12 2017-01-04 Lilly Co Eli Compuestos de azetidiniloxifenilpirrolidina
WO2021036953A1 (fr) * 2019-08-23 2021-03-04 湖北生物医药产业技术研究院有限公司 Composé phénylpyrrolidine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258833B1 (en) * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
CN101166737A (zh) * 2004-10-20 2008-04-23 记忆药物公司 磷酸二酯酶4抑制剂
CA2623657A1 (fr) 2005-09-29 2007-04-12 Bayer Healthcare Ag Inhibiteurs pde et combinaisons de ceux-ci pour traiter des troubles urinaires
TW201206440A (en) * 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
TWI617553B (zh) * 2013-03-13 2018-03-11 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物

Also Published As

Publication number Publication date
BR112017003010A2 (pt) 2017-12-12
AU2015312229B2 (en) 2017-11-16
ECSP17013015A (es) 2018-03-31
EA031089B1 (ru) 2018-11-30
JP2017525747A (ja) 2017-09-07
CN107001327B (zh) 2022-09-02
IL250356A0 (en) 2017-03-30
MX2017002688A (es) 2017-05-30
US10065942B2 (en) 2018-09-04
CO2017001097A2 (es) 2017-04-28
NZ728359A (en) 2018-08-31
CL2017000467A1 (es) 2017-10-20
TWI570119B (zh) 2017-02-11
US20170233373A1 (en) 2017-08-17
WO2016036596A1 (fr) 2016-03-10
PE20170442A1 (es) 2017-04-26
SG11201701608RA (en) 2017-03-30
CR20170051A (es) 2017-04-26
TN2017000045A1 (en) 2018-07-04
AU2015312229A1 (en) 2017-02-02
EP3189044A1 (fr) 2017-07-12
EP3189044B1 (fr) 2018-08-01
ES2688167T3 (es) 2018-10-31
DOP2017000037A (es) 2017-02-28
CN107001327A (zh) 2017-08-01
TW201619149A (zh) 2016-06-01
CA2956517A1 (fr) 2016-03-10
JP6364545B2 (ja) 2018-07-25
PH12017500400A1 (en) 2017-07-17
EA201790143A1 (ru) 2017-06-30
WO2016033776A1 (fr) 2016-03-10
KR20170038884A (ko) 2017-04-07
AP2017009774A0 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
EP3307266A4 (fr) Nouvelles polythérapies à base de cannabinoïdes pour le myélome multiple (mm)
IL248924A0 (en) 1-((r4,s3)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidine-3-yl)-3-(4-methyl-3-(2-methylpyrimidine-5-yl)- 1-phenyl-h1-pyrazol-5-yl)urea as a trka kinase inhibitor
EP3634701A4 (fr) Établi de sciage
MX2019009606A (es) Bis-compuestos para dispositivos opticamente activos.
EP3230921A4 (fr) Masquage multiplicatif pour opérations cryptographiques
EP3162394A4 (fr) Double canule intégrée pour ecmo
EP3486117A4 (fr) Ensemble tablette
MX2019012665A (es) Compuestos organicos.
EP3590944A4 (fr) Dérivé d'azétidine
IL261782A (en) Carbapenem compounds, preparations containing them and their uses
MA40606A (fr) (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyéthyl]-4-(4-méthoxy-3-{[1-(5-méthylpyridin-2-yl)azétidin-3-yl]oxy}phényl) -3-méthylpyrrolidin-1-yl]-3-oxopropane-1,2-diol cristallin
EP3415877B8 (fr) Machine de depot
EP3147267A4 (fr) Composition de verre pour fibre de verre
EP3104712A4 (fr) Procédé amélioré de synthèse de 1-benzyl-3-(1-(isoxazol-4-ylméthyl)-1h-pyrazol-4-yl)imidazolidine-2,4-diones substituées
AU2018297022A1 (en) Table top
ZA201700527B (en) Crystalline (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyethyl]-4-(4-methoxy-3-{[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl) -3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol
EP3761893A4 (fr) Canules chirurgicales améliorées
AU2014232502A8 (en) Process for the preparation of 4-amino-1-((1S,4R, 5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one
EP3744470A4 (fr) Préforme de brasure
EP3845136A4 (fr) Canule de travail à canaux multiples
EP3414297A4 (fr) Compositions amovibles à base aqueuse
MX2018005376A (es) Derivados de azetidina para formacion de imágenes de tau.
EP3206683A4 (fr) Nouveaux procédés, composés et compositions d'anesthésie
AU2018298939B2 (en) Fibre-forming plate
AU2017903047A0 (en) Medicinal Cannabis